Cell News and Research

RSS

Amgen to present its four Phase 3 clinical trial results

Amgen today announced it will present detailed data from four Phase 3 studies as well as other data at the ECCO 15 - ESMO 34 European Multidisciplinary Congress, September 20 - 24, 2009 in Berlin, Germany.

16 Sep 2009

Cyntellect announces commercial availability of Stem Cell Manager

Cyntellect, Inc., a privately-held life sciences company commercializing products to advance life science and stem cell research, biopharmaceutical production, and drug discovery, announced today the commercial availability of Stem Cell Manager powered by LEAP.

16 Sep 2009

Cryosurgery: Primary treatment option for prostate cancer

After years of innovation and intensive research, a team of Binghamton University (BU) researchers working with Cell Preservation Services, Inc., Owego, NY has broken extraordinary new ground in the recognition of cryosurgery as a primary treatment option for prostate cancer.

16 Sep 2009

FDA provides Orphan-Drug designation for Keryx' KRX-0401 to treat multiple myeloma

Keryx Biopharmaceuticals, Inc. today announced that KRX-0401 (perifosine) has received Orphan-Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma. In August, the Company announced that it had reached an agreement with the FDA regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial in relapsed/refractory multiple myeloma and that the study is expected to start by year-end.

16 Sep 2009

Keryx Biopharmaceuticals receives orphan-drug designation for a multiple myeloma drug

AEterna Zentaris Inc., ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc., its partner and licensee for perifosine in the North American market, has received orphan-drug designation for this compound from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma.

16 Sep 2009

Poniard Pharmaceuticals to present its corporate overview

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman and chief executive officer, will provide a corporate overview at the 2009 UBS Global Life Sciences Conference on Wednesday, September 23, 2009 at 3:00 p.m. Eastern Time at the Grand Hyatt Hotel in New York City.

16 Sep 2009

Children's Hospital enrolls patients for ExCell clinical study

Children's Hospital of Colorado and the Gamida Cell-Teva Joint Venture announced today that Children's Hospital is enrolling patients for the ExCell study. Children's Hospital is the 24th in a series of cord blood transplant sites worldwide, five of which are children's centers, participating in the study in the U.S., Spain, Italy, Hungary and Israel.

16 Sep 2009

Applied Biosystems launches MeltDoctor High-Resolution Melt Reagents for scanning DNA

Applied Biosystems, part of Life Technologies Corporation (NASDAQ:LIFE), today announced the launch of genomic analysis tools that will help researchers in studies that associate genetic variation with specific diseases. These new tools, known as the MeltDoctor™ High-Resolution Melt (HRM) Reagents, are for research use only and are part of a PCR-based workflow that enables researchers to cost-effectively scan DNA from a variety of biological sample types to detect the smallest genetic variations among samples.

16 Sep 2009

CEL-SCI to commence its LEAPS-H1N1 clinical trial following FDA approval

CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today that the U.S. Food and Drug Administration (FDA) has indicated that the Company can proceed with its first clinical trial to evaluate the effect of its investigational LEAPS-H1N1 treatment on the white blood cells of hospitalized H1N1 patients.

16 Sep 2009

Santaris Pharma establishes its operations in the U.S.

Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced it has established operations in the United States. Internally and through its partners, the Company has a robust drug development pipeline including programs to treat metabolic disorders, infectious and inflammatory diseases, cancer and rare genetic disorders.

16 Sep 2009

Medivir presented preclinical data from its cathepsin K inhibitor program at the ASBMR meeting

Medivir (STO:MVIRB) presented preclinical data on two candidate drugs (MIV-710, MIV-711) from its cathepsin K inhibitor program in a poster session during the ASBMR (American Society for Bone and Mineral Research) meeting.

16 Sep 2009

GENova in advanced negotiations to acquire patents from TheraGlass

GENova Biotherapeutics Inc. ("GENova") is pleased to announce that it is in advanced negotiations to acquire a number of patents from TheraGlass Ltd., a company that produces a ground-breaking regenerative bioactive material with exciting potential applications.

16 Sep 2009

Precise T cell correlates of protection need to be identified for vaccine design

T cells are key players in the immune response to HIV, which are able to delete infected cells. This capacity is used for vaccine development against HIV. "To date however, success of this strategy remains elusive. Our understanding of T cell efficacy is still limited, and we need to identify precise T cell correlates of protection that could guide rationale vaccine design", says Victor Appay, Group leader HIV Pathogenesis and Immunosenescence, Hopital Pitie-Salpetriere, Paris, at the 2nd European Congress of Immunology ECI 2009 in Berlin.

16 Sep 2009

IntrinsiQ's first IntelliView 360 research study results released

IntrinsiQ, the company improving the quality and understanding of cancer care, today announced the findings of the company’s first IntelliView 360 research study. The biggest outcome: Oncologists believe they treat lung cancer patients in the maintenance setting three times more often than they actually do.

16 Sep 2009

Toll-like receptors that activate immune cells being developed as alternative cure to cancer

A Toll-like receptor (TLR) agonist, called imiquimod, which activates dendritic cells, is in clinical use as a topical application for basal cell carcinoma. In addition, a number of TLR agonists have been evaluated in clinical trials as an adjuvant for cancer vaccines.

16 Sep 2009

Standardization of recycling policies can extend the life of electronic products

Processes and policies governing the reuse and recycling of electronic products need to be standardized worldwide to stem and reverse the growing problem of illegal and harmful e-waste processing practices in developing countries, according to experts behind the world's first international e-waste academy

16 Sep 2009

Genetically removing the osteopontin protein prevents lung diseases

In a development that could lead to a novel approach to the treatment of a devastating lung disease, biochemists at The University of Texas Health Science Center at Houston report they are the first to link the osteopontin (OPN) protein to chronic obstructive pulmonary disease (COPD).

16 Sep 2009

Immune response at tumour site predicts cancer progression in colorectal cancer patients

The immune reaction at tumour site determines cancer evolution and clinical outcome in patients with colorectal cancer, regardless of the local extent and spread of the tumour, according to the findings of Jérôme Galon, INSERM Research Director, Paris, and co-workers.

16 Sep 2009

Stem cells - the answer to autoimmune diseases and cancer in the future

Stem cells are multipotent cells of the immune system. Scientists hope to use them for curing autoimmune diseases, cancer and innate genetic defects in the future.

16 Sep 2009

New cancer therapy involves remodelling blood vessels and activating immune cells

Reversing or re-arranging the growth of these vessels in combination with specific immune strategies is a promising new strategy for cancer therapy, says Ruth Ganss, Professor at the Western Australian Institute for Medical Research, Perth, at the 2nd European Congress of Immunology ECI 2009 held in Berlin.

16 Sep 2009

Cell News and Research

Amgen to present its four Phase 3 clinical trial results

Cyntellect announces commercial availability of Stem Cell Manager

Cryosurgery: Primary treatment option for prostate cancer

FDA provides Orphan-Drug designation for Keryx' KRX-0401 to treat multiple myeloma

Keryx Biopharmaceuticals receives orphan-drug designation for a multiple myeloma drug

Poniard Pharmaceuticals to present its corporate overview

Children's Hospital enrolls patients for ExCell clinical study

Applied Biosystems launches MeltDoctor High-Resolution Melt Reagents for scanning DNA

CEL-SCI to commence its LEAPS-H1N1 clinical trial following FDA approval

Santaris Pharma establishes its operations in the U.S.

Medivir presented preclinical data from its cathepsin K inhibitor program at the ASBMR meeting

GENova in advanced negotiations to acquire patents from TheraGlass

Precise T cell correlates of protection need to be identified for vaccine design

IntrinsiQ's first IntelliView 360 research study results released

Toll-like receptors that activate immune cells being developed as alternative cure to cancer

Standardization of recycling policies can extend the life of electronic products

Genetically removing the osteopontin protein prevents lung diseases

Immune response at tumour site predicts cancer progression in colorectal cancer patients

Stem cells - the answer to autoimmune diseases and cancer in the future

New cancer therapy involves remodelling blood vessels and activating immune cells

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News